Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Apixaban and rivaroxaban, both direct-acting oral anticoagulants, are being increasingly
used in routine clinical practice because of their fixed dosing and favourable pharmacological
profiles. Differences in the risk of recurrent venous thromboembolism and major bleeding
events between the two drugs are currently unknown. We aimed to compare the effectiveness
and safety of apixaban and rivaroxaban in prevention of recurrent venous thromboembolism
and major bleeding events in patients with venous thromboembolism.